一分钟看懂
这是一项关于前列腺癌的II 期研究，登记的药物或干预包括enzalutamide；abiraterone acetate；prednisone；Leuprolide acetate，当前状态为研究进行中，已停止招募。登记地点显示中国湖北省、湖南省、南京有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
enzalutamide；abiraterone acetate；prednisone；Leuprolide acetate · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Site CN86003 · 湖北省
- Site CN86010 · 湖南省
- Site CN86005 · 南京
公开的入选条件
- * Subject must currently be receiving enzalutamide or assigned to receive enzalutamide (if on treatment suspension) for prostate cancer in a study sponsored by Astellas or Medivation and, based on the investigator's assessment, benefit from continued treatment
- * Subject is able to continue on the treatment regimen that they were receiving or were assigned to receive in the prior study. If in the investigator's assessment, a change is needed to the subject's regimen (e.g., dose change in Androgen deprivation therapy
- * Subject is able to swallow enzalutamide capsules and comply with study requirements.
- * Subject and female partner who is of childbearing potential must continue to use 2 forms of birth control, of which 1 must be highly effective and 1 must be a barrier method throughout the study and for 3 months after final enzalutamide administration.
- * Subject agrees to avoid sperm donation during the study and for at least 3 months after final enzalutamide administration.
- * Subject agrees not to participate in another interventional study while on treatment.
- Canada Specific:
- * Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written Informed Consent and privacy language as per national regulations (e.g., Health Insurance Portability and Accountability Act authorization for the United States sites) must
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT02960022；登记信息更新于 2026-09-11。